Interferon lambda concentrations in nasal lining fluid fell in or above the predicted therapeutic range with a nasally ...
England’s goal to eradicate bovine tuberculosis (TB) by 2038 remains alive – but only just. In the past decade, 274,000 ...
Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US This represents the first filing ...
News Medical on MSN
Decoding Sepsis: Unraveling Key Signaling Pathways for Targeted Therapies
Background： Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and ...
From 1 September 2025, a significant expansion of voluntary interferon-gamma blood testing has been available to cattle keepers in parts of England ...
CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company's anti-GDF ...
Autoimmune hepatitis (AIH) is a severe immune-mediated liver disease with limited treatment options beyond immunosuppressants, which carry significant ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New ...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treatedLAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE ...
Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive ...
IMNN-001 continues to show a favorable safety profile.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback